These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

638 related articles for article (PubMed ID: 34074331)

  • 21. Long-Term Safety and Efficacy of Tocilizumab in Early Systemic Sclerosis-Interstitial Lung Disease: Open-Label Extension of a Phase 3 Randomized Controlled Trial.
    Khanna D; Lin CJF; Furst DE; Wagner B; Zucchetto M; Raghu G; Martinez FJ; Goldin J; Siegel J; Denton CP
    Am J Respir Crit Care Med; 2022 Mar; 205(6):674-684. PubMed ID: 34851799
    [No Abstract]   [Full Text] [Related]  

  • 22. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An update on recent randomized clinical trials in systemic sclerosis.
    Boleto G; Avouac J; Allanore Y
    Joint Bone Spine; 2021 Oct; 88(5):105184. PubMed ID: 33887472
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How do I treat interstitial lung disease in systemic sclerosis?].
    Riemekasten G
    Z Rheumatol; 2021 Feb; 80(1):69-72. PubMed ID: 33340058
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease.
    Yamasaki Y; Kuwana M
    Expert Rev Clin Immunol; 2020 Jun; 16(6):547-560. PubMed ID: 32506975
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interstitial Lung Disease in Patients With Systemic Sclerosis: Toward Personalized-Medicine-Based Prediction and Drug Screening Models of Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD).
    Khedoe P; Marges E; Hiemstra P; Ninaber M; Geelhoed M
    Front Immunol; 2020; 11():1990. PubMed ID: 33013852
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective comparative study of the efficacy of JAK inhibitor (tofacitinib) in the treatment of systemic sclerosis-associated interstitial lung disease.
    Junfei Z; Meihua G; Shuai Z; Xiangting L; Zhidan L; Tianming C; Yajing L; Chu T; Lipu S
    Clin Rheumatol; 2023 Oct; 42(10):2823-2832. PubMed ID: 37335409
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of lung function decline on time to hospitalisation events in systemic sclerosis-associated interstitial lung disease (SSc-ILD): a joint model analysis.
    Kreuter M; Del Galdo F; Miede C; Khanna D; Wuyts WA; Hummers LK; Alves M; Schoof N; Stock C; Allanore Y
    Arthritis Res Ther; 2022 Jan; 24(1):19. PubMed ID: 35012623
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and risk factors of systemic sclerosis-associated interstitial lung disease in East Asia: A systematic review and meta-analysis.
    Qiu M; Nian X; Pang L; Yu P; Zou S
    Int J Rheum Dis; 2021 Dec; 24(12):1449-1459. PubMed ID: 34418313
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent advances in the management of systemic sclerosis-associated interstitial lung disease.
    Hoffmann-Vold AM; Distler O; Crestani B; Antoniou KM
    Curr Opin Pulm Med; 2022 Sep; 28(5):441-447. PubMed ID: 35855572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease.
    Kuwana M; Azuma A
    Mod Rheumatol; 2020 Mar; 30(2):225-231. PubMed ID: 31747840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process.
    Roofeh D; Barratt SL; Wells AU; Kawano-Dourado L; Tashkin D; Strand V; Seibold J; Proudman S; Brown KK; Dellaripa PF; Doyle T; Leonard T; Matteson EL; Oddis CV; Solomon JJ; Sparks JA; Vassallo R; Maxwell L; Beaton D; Christensen R; Townsend W; Khanna D
    Semin Arthritis Rheum; 2021 Dec; 51(6):1331-1341. PubMed ID: 34493396
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment for systemic sclerosis-associated interstitial lung disease.
    Roofeh D; Lescoat A; Khanna D
    Curr Opin Rheumatol; 2021 May; 33(3):240-248. PubMed ID: 33741803
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 2023 Brazilian Society of Rheumatology guidelines for the treatment of systemic sclerosis.
    Kayser C; de Oliveira Delgado SM; Zimmermann AF; Horimoto AMC; Del Rio APT; de Souza Müller C; Camargo CZ; Lupo CM; de Moraes DA; Do Rosário E Souza EJ; Santos FPST; Sekiyama JY; Lonzetti LS; de Oliveira Martins LV; Bezerra MC; Bredemeier M; Oliveira MC; da Fonseca Salgado MC; Miossi R; de Araújo Fontenele SM; Hax V; Dantas AT; Sampaio-Barros PD
    Adv Rheumatol; 2024 Jul; 64(1):52. PubMed ID: 38987832
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of antifibrotic therapies in the treatment of systemic sclerosis-associated interstitial lung disease.
    Boleto G; Avouac J; Allanore Y
    Ther Adv Musculoskelet Dis; 2022; 14():1759720X211066686. PubMed ID: 35111241
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New Era in Systemic Sclerosis Treatment: Recently Approved Therapeutics.
    Ebata S; Yoshizaki-Ogawa A; Sato S; Yoshizaki A
    J Clin Med; 2022 Aug; 11(15):. PubMed ID: 35956246
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Importance of mycophenolate mofetil for treatment of interstitial lung disease in systemic sclerosis].
    Schneider U; Siegert E; Gläser S; Krüger K; ; Krause A
    Z Rheumatol; 2021 Nov; 80(9):868-878. PubMed ID: 34545432
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 32.